How to buy Merus BV stock (MRUS)

Merus BV is a biotechnology business based in the US. Merus BV shares (MRUS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $52.82 – a decrease of 0.7% over the previous week. Merus BV employs 172 staff and has a trailing 12-month revenue of around $35.2 million.

Our top picks for where to buy Merus BV stock

Buy Merus BV stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Merus BV stock price (NASDAQ: MRUS)

Use our graph to track the performance of MRUS stocks over time.

Merus BV shares at a glance

• Key figures

Information last updated 2024-10-25.

Latest market close	$52.82
52-week range	$19.81 - $61.61
50-day moving average more info button	$51.09
200-day moving average more info button	$48.10
Wall St. target price	$87.79
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.89

Is it a good time to buy Merus BV stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Merus BV price performance over time

Historical closes compared with the close of $53.06 from 2024-10-25

1 week (2024-10-21)	2.83%
1 month (2024-09-30)	6.20%
3 months (2024-07-30)	-0.58%
6 months (2024-04-30)	18.15%

1 year (2023-10-30)	163.98%
2 years (2022-10-28)	148.99%
3 years (2021-10-26)	N/A
5 years (2019-10-30)	259.49%

Merus BV financials

Revenue TTM	$35.2 million
Gross profit TTM	$-107,838,000
Return on assets TTM	-19.62%
Return on equity TTM	-33.39%
Profit margin	0%
Book value	$11.01
Market Capitalization more info button	$3.6 billion

TTM: trailing 12 months

Merus BV share dividends

We're not expecting Merus BV to pay a dividend over the next 12 months.

Merus BV share price volatility

Over the last 12 months, Merus BV's shares have ranged in value from as little as $19.805 up to $61.61. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Merus BV's is 1.114. This would suggest that Merus BV's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Merus BV overview

Merus N. V. , a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc.

Frequently asked questions

What percentage of Merus BV is owned by insiders or institutions?
Currently 2.037% of Merus BV shares are held by insiders and 101.905% by institutions. How many people work for Merus BV?
Latest data suggests 172 work at Merus BV. When does the fiscal year end for Merus BV?
Merus BV's fiscal year ends in December. Where is Merus BV based?
Merus BV's address is: Uppsalalaan 17, Utrecht, Netherlands, 3584 CT What is Merus BV's ISIN number?
Merus BV's international securities identification number is: NL0011606264 What is Merus BV's CUSIP number?
Merus BV's Committee on Uniform Securities Identification Procedures number is: N5749R100